Pathology Ai - Revision history

Wordpad: BloomWiki: Pathology Ai

2026-04-25T01:55:24Z

BloomWiki: Pathology Ai

← Older revision		Revision as of 01:55, 25 April 2026
Line 1:		Line 1:
			<div style="background-color: #4B0082; color: #FFFFFF; padding: 20px; border-radius: 8px; margin-bottom: 15px;">
	{{BloomIntro}}		{{BloomIntro}}
	Computational pathology applies deep learning to the analysis of digitized tissue slides — whole-slide images (WSI) captured by digital pathology scanners. Pathology is the gold standard for cancer diagnosis, but it is labor-intensive, subjective, and facing a global workforce shortage. AI can analyze WSIs to classify cancer grade, predict molecular biomarkers, identify cell types, and predict patient survival — performing tasks that would take a pathologist hours in seconds. With FDA-cleared AI tools entering clinical pathology laboratories, the field is transitioning from research to real-world impact.		Computational pathology applies deep learning to the analysis of digitized tissue slides — whole-slide images (WSI) captured by digital pathology scanners. Pathology is the gold standard for cancer diagnosis, but it is labor-intensive, subjective, and facing a global workforce shortage. AI can analyze WSIs to classify cancer grade, predict molecular biomarkers, identify cell types, and predict patient survival — performing tasks that would take a pathologist hours in seconds. With FDA-cleared AI tools entering clinical pathology laboratories, the field is transitioning from research to real-world impact.
			</div>

	== Remembering ==		__TOC__

			<div style="background-color: #000080; color: #FFFFFF; padding: 20px; border-radius: 8px; margin-bottom: 15px;">
			== <span style="color: #FFFFFF;">Remembering</span> ==
	* '''Whole Slide Image (WSI)''' — A digitized pathology slide; gigapixel images (~100,000 × 100,000 pixels) scanned at 20–40× magnification.		* '''Whole Slide Image (WSI)''' — A digitized pathology slide; gigapixel images (~100,000 × 100,000 pixels) scanned at 20–40× magnification.
	* '''H&E staining''' — Hematoxylin and Eosin; the standard pathology stain coloring nuclei blue and cytoplasm pink.		* '''H&E staining''' — Hematoxylin and Eosin; the standard pathology stain coloring nuclei blue and cytoplasm pink.
Line 17:		Line 22:
	* '''Biomarker prediction from morphology''' — Predicting molecular alterations (MSI, BRCA mutation, TMB) from H&E histology without molecular testing.		* '''Biomarker prediction from morphology''' — Predicting molecular alterations (MSI, BRCA mutation, TMB) from H&E histology without molecular testing.
	* '''Cell segmentation (pathology)''' — Detecting and classifying individual cells (tumor, immune, stromal) within tissue; HoverNet, StarDist, CellViT.		* '''Cell segmentation (pathology)''' — Detecting and classifying individual cells (tumor, immune, stromal) within tissue; HoverNet, StarDist, CellViT.
			</div>

	== Understanding ==		<div style="background-color: #006400; color: #FFFFFF; padding: 20px; border-radius: 8px; margin-bottom: 15px;">
			== <span style="color: #FFFFFF;">Understanding</span> ==
	Pathology AI faces a unique challenge: slides are gigapixel-scale images far too large for direct processing by neural networks (a 40× WSI can be 100,000 × 100,000 pixels = 10 billion pixels). Two dominant strategies address this:		Pathology AI faces a unique challenge: slides are gigapixel-scale images far too large for direct processing by neural networks (a 40× WSI can be 100,000 × 100,000 pixels = 10 billion pixels). Two dominant strategies address this:

Line 30:		Line 37:

	'''FDA-cleared pathology AI''': Paige Prostate is the first FDA-authorized AI for prostate cancer detection. PathAI and other companies have cleared tools for various cancer types. Regulatory scrutiny is high: prospective clinical validation, algorithmic bias testing, and reader studies are required.		'''FDA-cleared pathology AI''': Paige Prostate is the first FDA-authorized AI for prostate cancer detection. PathAI and other companies have cleared tools for various cancer types. Regulatory scrutiny is high: prospective clinical validation, algorithmic bias testing, and reader studies are required.
			</div>

	== Applying ==		<div style="background-color: #8B0000; color: #FFFFFF; padding: 20px; border-radius: 8px; margin-bottom: 15px;">
			== <span style="color: #FFFFFF;">Applying</span> ==
	'''WSI classification with CLAM (MIL):'''		'''WSI classification with CLAM (MIL):'''
	<syntaxhighlight lang="python">		<syntaxhighlight lang="python">
Line 87:		Line 96:
	: '''Cell segmentation''' → HoverNet, StarDist, CellViT, CellPose		: '''Cell segmentation''' → HoverNet, StarDist, CellViT, CellPose
	: '''Commercial AI''' → Paige, PathAI, Aiforia, Ibex Medical Analytics		: '''Commercial AI''' → Paige, PathAI, Aiforia, Ibex Medical Analytics
			</div>

	== Analyzing ==		<div style="background-color: #8B4500; color: #FFFFFF; padding: 20px; border-radius: 8px; margin-bottom: 15px;">
			== <span style="color: #FFFFFF;">Analyzing</span> ==
	{\| class="wikitable"		{\| class="wikitable"
	\|+ Pathology AI Clinical Applications		\|+ Pathology AI Clinical Applications
Line 107:		Line 118:

	'''Failure modes''': Scanner variability — staining protocols and scanner calibration differ; models overfit to specific scanner characteristics. Stain normalization needed but can introduce artifacts. Tumor heterogeneity — sampling bias in biopsies; AI sees only a portion of the actual tumor. Interobserver variability — ground truth labels from pathologists have significant disagreement rates. Whole-slide processing bottleneck — gigapixel images require significant compute infrastructure.		'''Failure modes''': Scanner variability — staining protocols and scanner calibration differ; models overfit to specific scanner characteristics. Stain normalization needed but can introduce artifacts. Tumor heterogeneity — sampling bias in biopsies; AI sees only a portion of the actual tumor. Interobserver variability — ground truth labels from pathologists have significant disagreement rates. Whole-slide processing bottleneck — gigapixel images require significant compute infrastructure.
			</div>

	== Evaluating ==		<div style="background-color: #483D8B; color: #FFFFFF; padding: 20px; border-radius: 8px; margin-bottom: 15px;">
			== <span style="color: #FFFFFF;">Evaluating</span> ==
	Pathology AI evaluation:		Pathology AI evaluation:
	# '''AUC per clinical task''': detection, grading, biomarker prediction.		# '''AUC per clinical task''': detection, grading, biomarker prediction.
Line 115:		Line 128:
	# '''Multi-site validation''': test on slides from different labs, scanners, preparation protocols.		# '''Multi-site validation''': test on slides from different labs, scanners, preparation protocols.
	# '''Attention visualization''': inspect which tissue regions drive predictions — should match known diagnostic criteria.		# '''Attention visualization''': inspect which tissue regions drive predictions — should match known diagnostic criteria.
			</div>

	== Creating ==		<div style="background-color: #2F4F4F; color: #FFFFFF; padding: 20px; border-radius: 8px; margin-bottom: 15px;">
			== <span style="color: #FFFFFF;">Creating</span> ==
	Building a pathology AI pipeline:		Building a pathology AI pipeline:
	# Data: collect WSIs with slide-level labels (diagnosis, grade, biomarker status) from pathology archive.		# Data: collect WSIs with slide-level labels (diagnosis, grade, biomarker status) from pathology archive.
Line 129:		Line 144:
	[[Category:Pathology]]		[[Category:Pathology]]
	[[Category:Medical Imaging]]		[[Category:Medical Imaging]]
			</div>

Wordpad: BloomWiki: Pathology Ai

2026-04-23T14:36:19Z

BloomWiki: Pathology Ai

← Older revision		Revision as of 14:36, 23 April 2026
Line 109:		Line 109:

	== Evaluating ==		== Evaluating ==
	Pathology AI evaluation: ~~(1)~~ '''AUC per clinical task''': detection, grading, biomarker prediction. ~~(2)~~ '''Concordance with molecular tests''': for biomarker prediction models, compare to IHC/sequencing gold standards. ~~(3)~~ '''Reader study''': pathologists with and without AI assistance; measure diagnostic accuracy, time, confidence. ~~(4)~~ '''Multi-site validation''': test on slides from different labs, scanners, preparation protocols. ~~(5)~~ '''Attention visualization''': inspect which tissue regions drive predictions — should match known diagnostic criteria.		Pathology AI evaluation:
			# '''AUC per clinical task''': detection, grading, biomarker prediction.
			# '''Concordance with molecular tests''': for biomarker prediction models, compare to IHC/sequencing gold standards.
			# '''Reader study''': pathologists with and without AI assistance; measure diagnostic accuracy, time, confidence.
			# '''Multi-site validation''': test on slides from different labs, scanners, preparation protocols.
			# '''Attention visualization''': inspect which tissue regions drive predictions — should match known diagnostic criteria.

	== Creating ==		== Creating ==
	Building a pathology AI pipeline: ~~(1)~~ Data: collect WSIs with slide-level labels (diagnosis, grade, biomarker status) from pathology archive. ~~(2)~~ Preprocessing: tissue segmentation, patch extraction at 256×256 / 20×, feature extraction with UNI or CONCH. ~~(3)~~ MIL training: CLAM with 5-fold cross-validation; attention-based pooling. ~~(4)~~ Interpretability: generate attention heatmaps overlaid on WSI; pathologist verification. ~~(5)~~ Bias audit: evaluate performance across patient demographics. ~~(6)~~ Clinical validation: prospective reader study at target institution. ~~(7)~~ Regulatory: work with regulatory consultant on FDA 510(k) or De Novo pathway.		Building a pathology AI pipeline:
			# Data: collect WSIs with slide-level labels (diagnosis, grade, biomarker status) from pathology archive.
			# Preprocessing: tissue segmentation, patch extraction at 256×256 / 20×, feature extraction with UNI or CONCH.
			# MIL training: CLAM with 5-fold cross-validation; attention-based pooling.
			# Interpretability: generate attention heatmaps overlaid on WSI; pathologist verification.
			# Bias audit: evaluate performance across patient demographics.
			# Clinical validation: prospective reader study at target institution.
			# Regulatory: work with regulatory consultant on FDA 510(k) or De Novo pathway.

	[[Category:Artificial Intelligence]]		[[Category:Artificial Intelligence]]
	[[Category:Pathology]]		[[Category:Pathology]]
	[[Category:Medical Imaging]]		[[Category:Medical Imaging]]

Wordpad: BloomWiki: Pathology Ai

2026-04-23T14:21:02Z

BloomWiki: Pathology Ai

New page

{{BloomIntro}}
Computational pathology applies deep learning to the analysis of digitized tissue slides — whole-slide images (WSI) captured by digital pathology scanners. Pathology is the gold standard for cancer diagnosis, but it is labor-intensive, subjective, and facing a global workforce shortage. AI can analyze WSIs to classify cancer grade, predict molecular biomarkers, identify cell types, and predict patient survival — performing tasks that would take a pathologist hours in seconds. With FDA-cleared AI tools entering clinical pathology laboratories, the field is transitioning from research to real-world impact.

== Remembering ==
* '''Whole Slide Image (WSI)''' — A digitized pathology slide; gigapixel images (~100,000 × 100,000 pixels) scanned at 20–40× magnification.
* '''H&E staining''' — Hematoxylin and Eosin; the standard pathology stain coloring nuclei blue and cytoplasm pink.
* '''IHC (Immunohistochemistry)''' — Staining technique detecting specific proteins; used for biomarker testing (HER2, PD-L1, ER/PR).
* '''Tumor grading''' — Assessing tumor aggressiveness from histological features; e.g., Gleason score (prostate), Bloom-Richardson (breast).
* '''Multiple Instance Learning (MIL)''' — A weakly-supervised framework handling gigapixel WSI by treating each slide as a bag of smaller patches.
* '''Patch-based classification''' — Dividing WSI into tiles (e.g., 256×256 pixels) and classifying each; used for training with slide-level labels.
* '''CLAM (Clustering-constrained Attention Multiple Instance Learning)''' — A widely used MIL framework for WSI classification.
* '''Attention mechanism (pathology)''' — Identifies which patches are most diagnostically relevant within a slide.
* '''PathAI''' — A commercial computational pathology company with FDA-cleared tools; founded by Andrew Beck.
* '''Paige''' — First FDA-authorized AI for prostate cancer pathology; detects cancer in prostate biopsies.
* '''Foundation models (pathology)''' — CONCH, UNI, Phikon — vision transformers pre-trained on millions of pathology images; strong feature extractors.
* '''Pan-cancer classification''' — Predicting tumor type directly from histology across multiple cancer types.
* '''Biomarker prediction from morphology''' — Predicting molecular alterations (MSI, BRCA mutation, TMB) from H&E histology without molecular testing.
* '''Cell segmentation (pathology)''' — Detecting and classifying individual cells (tumor, immune, stromal) within tissue; HoverNet, StarDist, CellViT.

== Understanding ==
Pathology AI faces a unique challenge: slides are gigapixel-scale images far too large for direct processing by neural networks (a 40× WSI can be 100,000 × 100,000 pixels = 10 billion pixels). Two dominant strategies address this:

'''Patch-based approaches''': Extract thousands of smaller patches (256×256 or 512×512 pixels) from each slide. Train a CNN or ViT on each patch individually. Aggregate patch-level predictions to a slide-level diagnosis. This works but requires patch-level annotations, which are expensive and often unavailable.

'''Multiple Instance Learning (MIL)''': The dominant approach for slide-level labels. Each slide is a "bag" of patches. The bag label (e.g., cancer present) is known, but which patches contain cancer is unknown. MIL aggregates patch features using attention or pooling to produce a slide-level prediction. CLAM's attention mechanism additionally identifies which patches are driving the prediction — providing weak localization.

'''Pathology foundation models''': Pre-trained on millions of pathology patches using self-supervised learning (DINO, MAE, DINOv2), models like UNI, CONCH, and Prov-GigaPath learn rich histological feature representations. These serve as feature extractors for downstream tasks with minimal labeled data — a major advance for data-scarce pathology problems.

'''Biomarker prediction from morphology''': Neural networks trained on paired (WSI, molecular test result) data can predict molecular biomarkers from histology alone. TCGA-trained models predict microsatellite instability (MSI), BRAF mutation, HER2 amplification, and survival from H&E slides without any molecular testing. These predictions are not yet clinical-grade but suggest deep morphological correlates of molecular biology.

'''FDA-cleared pathology AI''': Paige Prostate is the first FDA-authorized AI for prostate cancer detection. PathAI and other companies have cleared tools for various cancer types. Regulatory scrutiny is high: prospective clinical validation, algorithmic bias testing, and reader studies are required.

== Applying ==
'''WSI classification with CLAM (MIL):'''
<syntaxhighlight lang="python">
import torch
import torch.nn as nn
import torch.nn.functional as F

class Attn_Net_Gated(nn.Module):
"""Gated attention network for MIL aggregation."""
def __init__(self, L=1024, D=256, dropout=0.25):
super().__init__()
self.attention_a = nn.Sequential(nn.Linear(L, D), nn.Tanh(), nn.Dropout(dropout))
self.attention_b = nn.Sequential(nn.Linear(L, D), nn.Sigmoid(), nn.Dropout(dropout))
self.attention_c = nn.Linear(D, 1)

def forward(self, x):
a = self.attention_a(x)
b = self.attention_b(x)
A = self.attention_c(a * b) # Gated attention scores
return A, x # (N, 1), (N, L)

class CLAM_SB(nn.Module):
"""CLAM single-branch for binary WSI classification."""
def __init__(self, feature_dim=1024, n_classes=2, dropout=0.25):
super().__init__()
self.attention_net = Attn_Net_Gated(L=feature_dim, D=256, dropout=dropout)
self.classifiers = nn.Linear(feature_dim, n_classes)
self.instance_classifier = nn.Linear(feature_dim, 2) # For instance-level clustering

def forward(self, h):
# h: (N, feature_dim) — patch embeddings from pre-trained feature extractor
A, h = self.attention_net(h)
A = F.softmax(A, dim=0).transpose(0, 1) # Softmax over patches: (1, N)
M = torch.mm(A, h) # Weighted aggregation: (1, feature_dim)
logits = self.classifiers(M) # Slide-level prediction
Y_hat = torch.argmax(logits, dim=1)
Y_prob = F.softmax(logits, dim=1)
return logits, Y_prob, Y_hat, A # A contains attention scores for visualization

# Feature extraction pipeline
# 1. Segment tissue from background (Otsu thresholding)
# 2. Extract non-overlapping 256×256 patches at 20× magnification
# 3. Extract features using pathology foundation model (UNI, CONCH, ResNet50-ImageNet)
# 4. Feed patch features to CLAM for WSI-level prediction

# Using UNI (pre-trained ViT on 100K pathology images)
# import timm
# uni = timm.create_model("hf_hub:MahmoodLab/uni", pretrained=True)
</syntaxhighlight>

; Computational pathology tools
: '''WSI viewing''' → QuPath (open-source), Aperio ImageScope, SlideViewer
: '''MIL frameworks''' → CLAM (GitHub), TransMIL, DTFD-MIL
: '''Foundation models''' → UNI, CONCH (Mahmood Lab), Prov-GigaPath (Microsoft/Providence)
: '''Cell segmentation''' → HoverNet, StarDist, CellViT, CellPose
: '''Commercial AI''' → Paige, PathAI, Aiforia, Ibex Medical Analytics

== Analyzing ==
{| class="wikitable"
|+ Pathology AI Clinical Applications
! Application !! AI Performance !! Clinical Status
|-
| Prostate cancer detection || AUC 0.97 (Paige) || FDA authorized
|-
| Breast cancer mitosis counting || Expert-level || CE marked (several)
|-
| Colorectal cancer grading || High || Research → clinical
|-
| MSI prediction from H&E || AUC ~0.85 || Research
|-
| Cell type quantification || High (specialized tools) || Used in trials
|-
| Survival prediction || C-index 0.65-0.75 || Research
|}

'''Failure modes''': Scanner variability — staining protocols and scanner calibration differ; models overfit to specific scanner characteristics. Stain normalization needed but can introduce artifacts. Tumor heterogeneity — sampling bias in biopsies; AI sees only a portion of the actual tumor. Interobserver variability — ground truth labels from pathologists have significant disagreement rates. Whole-slide processing bottleneck — gigapixel images require significant compute infrastructure.

== Evaluating ==
Pathology AI evaluation: (1) '''AUC per clinical task''': detection, grading, biomarker prediction. (2) '''Concordance with molecular tests''': for biomarker prediction models, compare to IHC/sequencing gold standards. (3) '''Reader study''': pathologists with and without AI assistance; measure diagnostic accuracy, time, confidence. (4) '''Multi-site validation''': test on slides from different labs, scanners, preparation protocols. (5) '''Attention visualization''': inspect which tissue regions drive predictions — should match known diagnostic criteria.

== Creating ==
Building a pathology AI pipeline: (1) Data: collect WSIs with slide-level labels (diagnosis, grade, biomarker status) from pathology archive. (2) Preprocessing: tissue segmentation, patch extraction at 256×256 / 20×, feature extraction with UNI or CONCH. (3) MIL training: CLAM with 5-fold cross-validation; attention-based pooling. (4) Interpretability: generate attention heatmaps overlaid on WSI; pathologist verification. (5) Bias audit: evaluate performance across patient demographics. (6) Clinical validation: prospective reader study at target institution. (7) Regulatory: work with regulatory consultant on FDA 510(k) or De Novo pathway.

[[Category:Artificial Intelligence]]
[[Category:Pathology]]
[[Category:Medical Imaging]]